TCGA-55-8091-01A-11R-2241-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 74
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.600
- ANGIOGENESIS+0.560
- INFLAMMATORY_RESPONSE+0.470
- IL6_JAK_STAT3_SIGNALING+0.460
- TNFA_SIGNALING_VIA_NFKB+0.460
- KRAS_SIGNALING_UP+0.450
- INTERFERON_GAMMA_RESPONSE+0.440
- COAGULATION+0.430
- ALLOGRAFT_REJECTION+0.380
- INTERFERON_ALPHA_RESPONSE+0.370
Top 10 suppressed
- MYC_TARGETS_V2-0.700
- E2F_TARGETS-0.650
- MYC_TARGETS_V1-0.600
- G2M_CHECKPOINT-0.530
- OXIDATIVE_PHOSPHORYLATION-0.460
- DNA_REPAIR-0.430
- UNFOLDED_PROTEIN_RESPONSE-0.290
- MITOTIC_SPINDLE-0.270
- PI3K_AKT_MTOR_SIGNALING-0.250
- GLYCOLYSIS-0.150
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1797302 | — | cohortMD2 | 0.945 |
| 2 | 2eaa09cd-8e3e-4de9-ab96-7a290d780a01 | — | — | 0.944 |
| 3 | TCGA-A2-A0EN-01A-13R-A084-07 | — | A | 0.944 |
| 4 | SRR1797296 | — | cohortMD2 | 0.936 |
| 5 | ERR2208937 | — | — | 0.935 |
| 6 | TCGA-38-4626-01A-01R-1206-07 | — | cohortMD2 | 0.934 |
| 7 | TCGA-49-6744-01A-11R-1858-07 | — | cohortA1 | 0.933 |
| 8 | SRR25617929 | — | A | 0.932 |
| 9 | TCGA-AO-A03U-01B-21R-A10J-07 | — | D | 0.931 |
| 10 | TCGA-CX-7085-01A-21R-2016-07 | — | — | 0.930 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.600 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.560 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.470 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.460 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.460 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.450 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.440 | Idelalisib | — uncovered |
| COAGULATION | 0.430 | Binimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.380 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.370 | Inavolisib | — uncovered |
| APOPTOSIS | 0.360 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.360 | Inavolisib | — uncovered |
| COMPLEMENT | 0.350 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.310 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.310 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.300 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.290 | Inavolisib | — uncovered |
| HYPOXIA | 0.290 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.250 | Remibrutinib | — uncovered |